Pharma market sees growth of 1.8 per cent in September 2013

According to IMS Health, the pharma market was reported at Rs 6834 crores for the month of September 2013, with a growth of 1.8 per cent.

Therapy	September 2013
	Value Rs Crore	Contribution %	Growth %
Total Market	6834	100	1.8
Acute	4853	71	-2.8
Chronic	1981	29	15.2
Source: IMS Health TSA, September 2013.

For the first time in 2013, IMS sees that the MAT growth for the industry has dipped below the 10 per cent mark.

A combination of factors driven primarily by the weak overall economic growth, the DPCO 2013 regulation and the ban on certain molecules has contributed to this dwindling growth.

According to Kumar Hinduja, Sr Director Strategy Planning and Business Development, the pharma market has remained almost static in the July-September 2013 quarter. The NLEM segment still continues to impact market uptake, following the DPCO 2013 notification. Products impacted by this regulation posted a decline of seven per cent in current month, as compared to September 2012 – on account of price reduction as well as the delay in delivery of newer stocks with changed prices. On the other hand, the non-NLEM segment which contributes ~80 per cent of the market, has posted a growth of five per cent over the same period last year.”

Hinduja further said, “The seasonal factor also appears to have contributed to some extent to the lower monthly growth of 1.8 per cent. The market in September 2012 had posted a strong performance on the back of a monsoon revival across the country; the monsoon this year in September has been relatively milder. This has resulted in a decline in certain therapies slowing down, and consequently impacting the market performance. For example, anti-infectives and respiratory drugs which contribute to 24 per cent of the market, de-grew by 19 per cent and seven per cent respectively as compared to September 12.”

For the period MAT September 2013, the pharma market was reported at Rs 76,198 crore, with a growth of 9.3 per cent, over the same period last year.

For the month of September 2013, Sun Pharma was the fastest growing corporations among the Top 10, while six of these companies posted negative growths.

Zydus Cadila climbed one rank in the month of September 2013, at the expense of Ranbaxy, which dropped by one rank; ranks of other corporations remained unchanged for the month.

For the month, both local companies and MNCs have grown at almost the same pace (2.0 per cent vs. 1.3 per cent)

For the month of September 2013, anti diabetics, cardiac and derma therapies have shown strong growths. On the other hand anti-infectives and respiratory drugs have declined as compared to last year.

EP News Bureau – Mumbai